Business
HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia
HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n TORONTO, Nov. 17, 2020\n \n \n \n \n \n \n \n first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia\n \n \n \n \n \n \n once-monthly dosing may help improve treatment compliance\n \n \n \n \n \n \n PERSERIS is a first-line treatment option for schizophrenia and is commercially complementary to Clozaril®, which is for treatment resistant schizophrenia\n \n \n \n \n \n \n TORONTO\n \n ,\n \n Nov. 17, 2020\n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Health Canada has approved the use of PERSERIS® (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults. HLS has in-licensed the exclusive rights to PERSERIS for the Canadian market from Indivior PLC (LON: INDV).\n \n \n Risperidone is a well-established treatment for schizophrenia, and PERSERIS delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended. Sustained therapeutic levels of risperidone are released over a one-month period from a single injection.\n \n \n \"We are pleased with Health Canada's approval of PERSERIS, which we believe has the potential to become a broadly used therapy for patients with schizophrenia,\" said\n \n Gilbert Godin\n \n , CEO of HLS. \"As a long-acting once-per-month injectable version of risperidone, PERSERIS may help enhance treatment compliance when compared to other daily treatment options\n \n 1\n \n . This opportunity will also allow us to directly leverage our existing commercial infrastructure, relationships and reach in the Canadian psychiatric market while delivering a new, clinically ...